Repligen Co. (NASDAQ:RGEN) Shares Sold by Zevenbergen Capital Investments LLC

Zevenbergen Capital Investments LLC lowered its position in Repligen Co. (NASDAQ:RGEN) by 12.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 112,747 shares of the biotechnology company’s stock after selling 16,223 shares during the period. Zevenbergen Capital Investments LLC’s holdings in Repligen were worth $16,229,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in RGEN. Vanguard Group Inc. lifted its holdings in shares of Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock valued at $734,251,000 after buying an additional 56,723 shares during the period. LPL Financial LLC raised its position in Repligen by 47.6% in the fourth quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company’s stock worth $4,873,000 after acquiring an additional 10,395 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Repligen during the 4th quarter worth $667,000. KLP Kapitalforvaltning AS acquired a new position in shares of Repligen during the 4th quarter worth $1,555,000. Finally, Sei Investments Co. increased its holdings in shares of Repligen by 12.7% in the 4th quarter. Sei Investments Co. now owns 219,604 shares of the biotechnology company’s stock valued at $31,610,000 after purchasing an additional 24,662 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Up 0.5 %

Shares of RGEN opened at $140.02 on Monday. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $198.00. The stock has a fifty day moving average of $156.18 and a two-hundred day moving average of $148.40. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market capitalization of $7.86 billion, a PE ratio of -274.55, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

Insider Transactions at Repligen

In other news, Director Margaret Pax purchased 250 shares of the stock in a transaction on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. TD Cowen initiated coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. Canaccord Genuity Group boosted their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Royal Bank of Canada raised their price target on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. Finally, JPMorgan Chase & Co. increased their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Repligen presently has a consensus rating of “Hold” and a consensus price target of $178.64.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.